Evidence map›Paper›PMID 38611865›Full record

ArticleMolecules (Basel, Switzerland)2024

Tetraethylenepentamine-Grafted Amino Terephthalic Acid-Modified Activated Carbon as a Novel Adsorbent for Efficient Removal of Toxic Pb(II) from Water.

Mutairah S Alshammari

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mutairah S AlshammariChemistry Department, College of Science, Jouf University, P.O. Box 2014, Sakaka 72341, Saudi Arabia.
Jouf University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, a new composite, tetraethylenepentamine (TEPA), was incorporated into amino terephthalic acid-modified activated carbon (ATA@AC) through a one-pot integration of TEPA with the COOH moiety of ATA@AC. This process resulted in the creation of a TEPA@ATA@AC composite for Pb(II) removal from an aquatic environment. Several techniques, including SEM, EDX, FT-IR, TGA, XRD, and Zeta potential, were employed to emphasize the chemical composition, morphology, and thermal durability of the as-synthesized TEPA@ATA@AC composite. The impact of experimental variables on the adsorption of Pb(II) ions was studied using batch adsorption. The uptake assessment suggested that the TEPA@ATA@AC composite exhibited superior Pb(II) removal performance with high removal efficiency (97.65%) at pH = 6.5, dosage = 0.02 g, equilibrium time = 300 min, and temperature = 298 K. The isotherm data exhibited good conformity with the Langmuir isotherm model, whereas the kinetics data displayed strong agreement with both pseudo-first-order and pseudo-second-order kinetics models. This reflected that the Pb((II) uptake by the TEPA@ATA@AC composite was caused by physisorption coupled with limited chemisorption. The greatest monolayer uptake capacity of the TEPA@ATA@AC composite was 432.8 mg/g. The thermodynamic findings indicated that the Pb(II) uptake on the TEPA@ATA@AC composite was an exothermic and feasible process. After five adsorption-desorption runs, the TEPA@ATA@AC composite maintained a superior uptake capacity (83.80%). In summary, the TEPA@ATA@AC composite shows promise as a potent adsorbent for effectively removing Cr(VI) from contaminated water, with impressive removal efficiency.

Indexed as

adsorptionisothermtetraethylenepentamine (TEPA)toxic Pb(II)

Identifiers

PMID38611865
PMCPMC11013411
OpenAlexW4393421170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.